blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3003289

EP3003289 - ADMINISTRATION OF OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS [Right-click to bookmark this link]
Former [2016/15]OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS FOR THE PARENTERAL TREATMENT OR PROPHYLAXIS OF BACTERIAL DISEASES
[2018/34]
StatusNo opposition filed within time limit
Status updated on  27.12.2019
Database last updated on 18.11.2024
FormerThe patent has been granted
Status updated on  18.01.2019
FormerGrant of patent is intended
Status updated on  26.09.2018
FormerExamination is in progress
Status updated on  08.09.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Morphochem GmbH
Gmunder Strasse 37-37a
81379 München / DE
[2019/25]
Former [2018/43]For all designated states
Morphochem Aktiengesellschaft für kombinatorische Chemie
Gmunder Strasse 37-37a
81379 München / DE
Former [2016/15]For all designated states
Morphochem Aktiengesellschaft Für Kombinatorische Chemie
Gmunder Strasse 37-37a
81379 München / DE
Inventor(s)01 / KAPSNER, Thomas
Grasslfinger Str. 7B
82194 Gröbenzell / DE
02 / DALHOFF, Axel
Obere Bergerheide 40
42113 Wuppertal / DE
03 / GRAMATTE, Thomas
Goetheallee 28a
01309 Dresden / DE
 [2016/15]
Representative(s)Forstmeyer, Dietmar, et al
Boeters & Lieck
Oberanger 32
80331 München / DE
[N/P]
Former [2016/15]Forstmeyer, Dietmar, et al
BOETERS & LIECK
Oberanger 32
80331 München / DE
Application number, filing date14723716.809.05.2014
[2016/15]
WO2014EP01253
Priority number, dateEP2013000276228.05.2013         Original published format: EP 13002762
EP2013000574510.12.2013         Original published format: EP 13005745
EP2013000574810.12.2013         Original published format: EP 13005748
[2016/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014191075
Date:04.12.2014
Language:EN
[2014/49]
Type: A1 Application with search report 
No.:EP3003289
Date:13.04.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 04.12.2014 takes the place of the publication of the European patent application.
[2016/15]
Type: B1 Patent specification 
No.:EP3003289
Date:20.02.2019
Language:EN
[2019/08]
Search report(s)International search report - published on:EP04.12.2014
ClassificationIPC:A61K31/00, A61K31/4375, A61K31/4709, A61P31/04
[2016/15]
CPC:
A61K31/4375 (EP,RU,US); C07F9/653 (US); A61K31/4709 (EP,RU,US);
A61P1/00 (EP,US); A61P1/12 (EP,US); A61P31/00 (EP,US);
A61P31/04 (EP,RU,US); Y02A50/30 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/15]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERABREICHUNG VON ANTIBAKTERIELLEN OXAZOLIDINON-CHINOLON-HYBRID-MITTELN[2018/34]
English:ADMINISTRATION OF OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS[2018/34]
French:L'ADMINISTRATION D'ANTIBACTÉRIENS HYBRIDES DE OXAZOLIDINONE-QUINOLONE[2018/34]
Former [2016/15]ANTIBAKTERIELLE OXAZOLIDINON-CHINOLON-HYBRID-MITTEL ZUR PARENTERALEN BEHANDLUNG ODER PROPHYLAXE BAKTERIELLER ERKRANKUNGEN
Former [2016/15]OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS FOR THE PARENTERAL TREATMENT OR PROPHYLAXIS OF BACTERIAL DISEASES
Former [2016/15]ANTIBACTÉRIENS HYBRIDES À BASE D'OXAZOLIDINONE-QUINOLONE POUR LE TRAITEMENT PARENTÉRAL OU LA PROPHYLAXIE DE MALADIES BACTÉRIENNES
Entry into regional phase17.12.2015National basic fee paid 
17.12.2015Designation fee(s) paid 
17.12.2015Examination fee paid 
Examination procedure17.12.2015Examination requested  [2016/15]
30.09.2016Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
30.09.2016Despatch of communication of loss of particular rights: Claims {1}
28.11.2016Amendment by applicant (claims and/or description)
11.09.2017Despatch of a communication from the examining division (Time limit: M06)
16.03.2018Reply to a communication from the examining division
27.09.2018Communication of intention to grant the patent
07.01.2019Fee for grant paid
07.01.2019Fee for publishing/printing paid
07.01.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19157832.7  / EP3517106
Opposition(s)21.11.2019No opposition filed within time limit [2020/05]
Request for further processing for:28.11.2016Request for further processing filed
28.11.2016Full payment received (date of receipt of payment)
Request granted
14.12.2016Decision despatched
Fees paidRenewal fee
29.03.2016Renewal fee patent year 03
23.05.2017Renewal fee patent year 04
22.05.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL20.02.2019
LV20.02.2019
MK20.02.2019
MT20.02.2019
SM20.02.2019
[2022/31]
Former [2021/34]AL20.02.2019
LV20.02.2019
MT20.02.2019
SM20.02.2019
Former [2019/52]AL20.02.2019
LV20.02.2019
SM20.02.2019
Former [2019/50]AL20.02.2019
LV20.02.2019
Former [2019/39]LV20.02.2019
Cited inInternational search[XY]WO2004096221  (MORPHOCHEM AG KOMB CHEMIE [DE], et al) [X] 2,4-13,15-29,32 * p. 21, l.26-28; p. 64, example 73 * [Y] 1-13,15-32;
 [XY]WO2005058888  (MORPHOCHEM AG [DE], et al) [X] 2,4-13,15-29,32 * example 7; p. 12, l. 32 * [Y] 1-13,15-32;
 [XY]WO2009136379  (ACTELION PHARMACEUTICALS LTD [CH], et al) [X] 2,4-13,15,17-25,29-32 * claims, examples *[Y] 1-13,15-32
by applicantWO02059116
 WO03002560
 WO03031443
 WO03032962
 WO2004096221
 WO2005023801
 WO2005058888
 WO2007017828
 WO2008056335
 WO2008062379
 WO2009136379
 US8329908
 US8513231
    - NATIONAL HOSPITAL DISCHARGE SURVEY ANNUAL FILES 1996-2009, (20130522), URL: http://www.cdc/nchs/nhds.htm
    - TILLOTSON GS; TILLOTSON J, "Clostridium difficile - a moving target", F1000 MEDICINE REPORTS, (2011), vol. 3, page 6
    - PEPIN J; ALARY ME; VALIQUETTE L; RAICHE E; RUEL J; FULOP K; GODIN D; BOURASSA C, "Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada", CLIN INFECT DIS, (2005), vol. 40, pages 1591 - 1597
    - MILLER M; GRAVEL D; MULVEY M; TAYLOR G; BOYD D; SIMOR A; GARDAM M; MCGEER A; HUTCHINSON J; MOORE D, "Health care-associated Clostridium difficile infection in Canada: Patient age and infecting strain type are highly predictive of severe outcome and mortality", CLIN INFECT DIS, (2010), vol. 50, pages 194 - 201
    - YOO J; LIGHTNER AL, "Clostridium difficile infections: what every clinician should know", THE PERMANENTE JOURNAL, (2010), vol. 14, pages 35 - 40
    - WENISCH JM; SCHMID D; TUCEK G; KUO HW; ALLERBERGER F; MICHL V; TESIK P; LAFERL H; WENISCH C., "A prospective cohort study on hospital mortality due to Clostridium difficile infection.", INFECTION, (2012), vol. 40, no. 5, pages 479 - 484
    - DENÈVE C; JANOIR C; POILANE I; FANTINATO C; COLLIGNON A, "New trends in Clostridium difficile virulence and pathogenesis", INT J ANTIMICROB AGENTS, (2009), vol. 33, doi:doi:10.1016/S0924-8579(09)70012-3, pages S24 - S28, XP026010678

DOI:   http://dx.doi.org/10.1016/S0924-8579(09)70012-3
    - STUART H. COHEN, MD; DALE N. GERDING, MD; STUART JOHNSON, MD; CIARAN P. KELLY, MD; VIVIAN G. LOO, MD; L. CLIFFORD MCDONALD, MD; JA, "Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA", INFECT CONTROL HOSP EPIDEMIOL, (2010), vol. 31, no. 5, doi:doi:10.1086/651706, pages 431 - 455, XP055144254

DOI:   http://dx.doi.org/10.1086/651706
    - PERFORMANCE STANDARDS FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING 11TH INFORMATIONAL SUPPLEMENT, (200101), vol. 21, no. 1, pages M100 - 511
    - NCCLS, (200701), vol. 27, no. 1, pages M100 - S16
    - KATO H; KATO N; WATANABE K; IWAI N; NAKAMURA H; YAMAMOTO T ET AL., "Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR", J CLIN MICROBIOL, (1998), vol. ;36, pages 2178 - 82, XP002629607
    - HUANG H; WEINTRAUB A; FANG H; NORD CE., "Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of Clostridium difficile infections.", J CLIN MICROBIOL, (2009), vol. 47, pages 3729 - 31
    - STUBBS SL; BRAZIER JS; O'NEILL GL; DUERDEN BI, "PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes", J CLIN MICROBIOL, (1999), vol. 37, pages 461 - 3, XP007906905
    - RASHID MU; LOZANO HM; WEINTRAUB A; NORD CE, "In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden", ANAEROBE, (2013), vol. 20, pages 32 - 5
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.